Presurgical propranolol modulates biomarkers associated with breast cancer progression. β-adrenergic signaling promotes invasion, epithelial-to-mesenchymal transition phenotype, and immune cell infiltration into the tumor microenvironment. Blockade of the β-adrenergic receptor signaling with propranolol, along with potential future combinatorial strategies, holds promise for reducing breast cancer progression and metastasis.
Bibliographical noteFunding Information:
This work was supported by funding from Irving Scholar Award (to K. Kalinsky).
© 2020 American Association for Cancer Research.
Copyright 2020 Elsevier B.V., All rights reserved.
PubMed: MeSH publication types
- Journal Article
- Research Support, Non-U.S. Gov't